Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure

. 2020 Oct 08 ; 383 (15) : 1413-1424. [epub] 20200828

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články, multicentrická studie, randomizované kontrolované studie, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/pmid32865377

BACKGROUND: Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of hospitalization for heart failure in patients regardless of the presence or absence of diabetes. More evidence is needed regarding the effects of these drugs in patients across the broad spectrum of heart failure, including those with a markedly reduced ejection fraction. METHODS: In this double-blind trial, we randomly assigned 3730 patients with class II, III, or IV heart failure and an ejection fraction of 40% or less to receive empagliflozin (10 mg once daily) or placebo, in addition to recommended therapy. The primary outcome was a composite of cardiovascular death or hospitalization for worsening heart failure. RESULTS: During a median of 16 months, a primary outcome event occurred in 361 of 1863 patients (19.4%) in the empagliflozin group and in 462 of 1867 patients (24.7%) in the placebo group (hazard ratio for cardiovascular death or hospitalization for heart failure, 0.75; 95% confidence interval [CI], 0.65 to 0.86; P<0.001). The effect of empagliflozin on the primary outcome was consistent in patients regardless of the presence or absence of diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (hazard ratio, 0.70; 95% CI, 0.58 to 0.85; P<0.001). The annual rate of decline in the estimated glomerular filtration rate was slower in the empagliflozin group than in the placebo group (-0.55 vs. -2.28 ml per minute per 1.73 m2 of body-surface area per year, P<0.001), and empagliflozin-treated patients had a lower risk of serious renal outcomes. Uncomplicated genital tract infection was reported more frequently with empagliflozin. CONCLUSIONS: Among patients receiving recommended therapy for heart failure, those in the empagliflozin group had a lower risk of cardiovascular death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes. (Funded by Boehringer Ingelheim and Eli Lilly; EMPEROR-Reduced ClinicalTrials.gov number, NCT03057977.).

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Komentář v

PubMed

Citace poskytuje Crossref.org

Nejnovějších 20 citací...

Zobrazit více v
Medvik | PubMed

The treatment with soluble guanylate cyclase stimulator BAY41-8543 prevents malignant hypertension and associated organ damage

. 2025 Jun 01 ; 43 (6) : 1030-1041. [epub] 20250408

Metabolic Consequences of Advanced Chronic Heart Failure and its Modification by Implantation of a Durable Left Ventricular Assist Device

. 2024 Nov ; 25 (11) : 388. [epub] 20241031

Heart failure care in the Central and Eastern Europe and Baltic region: status, barriers, and routes to improvement

. 2024 Aug ; 11 (4) : 1861-1874. [epub] 20240322

Effect of Sodium-Glucose Co-Transporter-2 Inhibitor on Estimated Plasma Volume in a Patient With Heart Failure With Reduced Ejection Fraction and a Patient With Heart Failure With Preserved Ejection Fraction

. 2024 Jul ; 47 (7) : e24303.

Sodium-glucose cotransporter 2 inhibitors induce anti-inflammatory and anti-ferroptotic shift in epicardial adipose tissue of subjects with severe heart failure

. 2024 Jun 28 ; 23 (1) : 223. [epub] 20240628

CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes

. 2024 Mar 19 ; 23 (1) : 104. [epub] 20240319

Left ventricular reverse remodelling and its predictors in non-ischaemic cardiomyopathy

. 2022 Aug ; 9 (4) : 2070-2083. [epub] 20220418

Metformin treatment is associated with improved outcome in patients with diabetes and advanced heart failure (HFrEF)

. 2022 Jul 29 ; 12 (1) : 13038. [epub] 20220729

Sodium Glucose Cotransporter-2 Inhibitors: Spotlight on Favorable Effects on Clinical Outcomes beyond Diabetes

. 2022 Mar 04 ; 23 (5) : . [epub] 20220304

The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial

. 2022 Mar ; 28 (3) : 568-574. [epub] 20220228

DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases

. 2022 Feb ; 36 (2) : 108101. [epub] 20211207

Complex Positive Effects of SGLT-2 Inhibitor Empagliflozin in the Liver, Kidney and Adipose Tissue of Hereditary Hypertriglyceridemic Rats: Possible Contribution of Attenuation of Cell Senescence and Oxidative Stress

. 2021 Sep 30 ; 22 (19) : . [epub] 20210930

Effects of Epoxyeicosatrienoic Acid-Enhancing Therapy on the Course of Congestive Heart Failure in Angiotensin II-Dependent Rat Hypertension: From mRNA Analysis towards Functional In Vivo Evaluation

. 2021 Aug 20 ; 9 (8) : . [epub] 20210820

The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus

. 2021 Jun ; 64 (6) : 1226-1234. [epub] 20210220

The effect of three major co-morbidities on quality of life and outcome of patients with heart failure with reduced ejection fraction

. 2021 Apr ; 8 (2) : 1417-1426. [epub] 20210129

Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: GALACTIC-HF baseline characteristics and comparison with contemporary clinical trials

. 2020 Nov ; 22 (11) : 2160-2171. [epub] 20201027

Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes

. 2020 Oct 23 ; 19 (1) : 185. [epub] 20201023

Zobrazit více v PubMed

ClinicalTrials.gov
NCT03057977

Najít záznam

Citační ukazatele

Nahrávání dat ...

Možnosti archivace

Nahrávání dat ...